1.2021-10 至 今，南京大学，现代生物研究院，研究员

2.2016-09 至 2021-09，中国药科大学，基础医学与临床药学学院，教授

3.2012-03 至 2016-08，美国加州大学圣迭戈分校，博士后，合作导师，Bernd Schnabl

4.2011-07 至 2012-02，上海药明康德新药研发公司，心血管部门，研究员

2018  国际青年研究者奖，美国肝病研究协会基金会

2017  江苏省“六大人才高峰”

2016  江苏省特聘教授

2015  “最佳摘要”奖，第17届酒精性肝病和肝硬化年会，南加州大学肝病研究中心

2011  “三好学生”，中科院上海药物研究所

2002  “二等国家奖学金”，中国药科大学

以下期刊的审稿人：Hepatology, Journal of Hepatology, Cell Reports Medicine, Gut Microbes, Acta Pharmaceutica Sinica B, PLOS ONE, Liver International, Free Radical Biology and Medicine, Acta Pharmacologica Sinica, International Immunopharmacology, Gut Pathogen, Digestive Diseases and Sciences, Pharmacology, Pharmacological Research, Diabetes & Metabolism, Cellular Immunology, Journal of Gastroenterology and Hepatology, European Journal of Pharmacology, The American Journal of Chinese Medicine, NPJ Biofilms and Microbiomes, Scientific Reports.

2017 至 今，青年编辑委员，Chinese Journal of Liver Diseases

1.Pan C#, Liu J#, Gao Y#, Yang M, Hu H, Liu C, Qian M, Yuan H, Yang S*, Zheng M*, Wang L*. Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cells-produced acetylcholine and smoking exposure in mice and humans. Cell Metabolism. 2023 Dec; 35(12): 2231-2249.

2.Pan C, Liu C, Jia W, Zhao D, Chen X, Zhu X, Yang M, Wang L*. Alcohol drinking alters oral microbiota to modulate the progression of alcohol-related liver disease. iScience. 2023 Oct; 26(10): 107977.

3.Liu J#, Zhang X#, Zhang Y#, Qian M, Yang M, Yang S, Wang L*. Farnesyl diphosphate synthase exacerbates nonalcoholic steatohepatitis via the activation of AHR-CD36 axis. FASEB J. 2023 Jul;37(7): e23035.

4.Zhang X#, Zuo R#, Xiao S, Wang L*. Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017–2018) and a controlled animal study. Nutrition & Metabolism (Lond). 2022 Dec 13;19(1):81.

5.Li Y#, Zhao D#, Qian M, Liu J, Pan C, Zhang X, Duan X, Zhang Y, Jia W, Wang L*. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. British Journal of Pharmacology. 2022 May;179(9):2054-2077.

6.Qian M#, Li J#, Zhao D#, Cai P#, Pan C, Jia W, Gao Y, Zhan Y, Zhan N, Zhang Y, Zhang Q, Wu D, Shan C, Zhang M, Schnabl B, Yang S*, Shen X*, Wang L*. Aryl hydrocarbon receptor deficiency in intestinal epithelial cells aggravates alcohol-related liver disease. Cellular and Molecular Gastroenterology and Hepatology. 2022;13(1):233-256.

- Previewed in “Interplay of gut microbes and aryl hydrocarbon receptor in alcohol-associated liver disease” (Cellular and Molecular Gastroenterology and Hepatology. 2022;13(1):343-345.) by Prof. Bin Gao (NIAAA)

7.Gao Y#, Qian M#, Wei Q#, Duan X, Wang S, Hu H, Liu J, Pan C, Zhang S, Qi L, Zhou J, Zhang H*, Wang L*. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacologica Sinica. 2020 Mar; 41(3): 336-347. Cover Story

8.Qian M#, Hu H#, Yao Y#, Zhao D, Wang S, Pan C, Duan X, Gao Y, Liu J, Zhang Y, Yang S, Qi LW, Wang L*. Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis. Liver International. 2020 Mar; 40: 622-637.

9.Zhang Y, Huang R, Cheng M, Wang L, Chao J, Li J, Zheng P, Xie P, Zhang Z, Yao H. Gut microbiota from NLRP3-deficient mice ameliorates depressive-like behaviors by regulating astrocyte dysfunction via circHIPK2. Microbiome. 2019 Aug; 7(1):116.

10.Qian M#, Lyu Q#, Liu Y, Hu H, Wang S, Pan C, Duan X, Gao Y, Qi LW, Liu W*, Wang L*. Chitosan oligosaccharide ameliorates nonalcoholic fatty liver disease (NAFLD) in diet-induced obese mice. Marine Drugs. 2019 Jul; 17(7), 391.

11.Wang L#*, Mazagova M#, Pan C#, Yang S#, Brandl K, Liu J, Reilly SM, Wang Y, Miao Z, Loomba R, Lu N, Guo Q, Liu J, Yu RT, Downes M, Evans RM, Brenner DA, Saltiel AR, Beutler B*, Schnabl B*. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proceedings of the National Academy of Sciences of the United States of America. 2019 Jul;116(30):15184-15193.

12.Bluemel S, Wang L, Kuelbs C, Moncera K, Torralba M, Singh H, Fouts DE, Schnabl B. Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes. 2019 Apr; 11(3), 265–275.

13.Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal C‐type Regenerating Islet Derived‐3 Lectins for Nonalcoholic Steatohepatitis. Hepatology Communications. 2018 Apr; 2(4): 393-406.

14.Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 lectins protect mice from alcohol-induced steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host & Microbe. 2016 Feb; 19(2):227-39.

- Highlighted by Nature Reviews Gastroenterology &Hepatology

- Previewed in “Alcohol lowers your (intestinal) inhibitions” (Cell Host & Microbe.    2016 Feb 10;19(2):131-3.) by Prof. Shipra Vaishnava (Brown University)

15. Wang L, Hartmann P, Haimerl M, Bathena S., Sjöwall C, Almer S, Alnouti Y, Hofmann A, and Schnabl B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. Journal of Hepatology. 2014 Jun; 60(6):1259-67.